Evelo Biosciences, Inc. (EVLO): Price and Financial Metrics
EVLO Price/Volume Stats
| Current price | $0.05 | 52-week high | $13.93 |
| Prev. close | $0.04 | 52-week low | $0.03 |
| Day low | $0.05 | Volume | 1,500 |
| Day high | $0.05 | Avg. volume | 43,205 |
| 50-day MA | $0.05 | Dividend yield | N/A |
| 200-day MA | $2.44 | Market Cap | 949.15K |
EVLO Stock Price Chart Interactive Chart >
Evelo Biosciences, Inc. (EVLO) Company Bio
Evelo Biosciences, Inc. focuses on the development of monocolonal microbials for the treatment of inflammatory diseases and cancer. It is involved in developing EDP1066 and EDP1815 for patients with psoriasis and atopic dermatitis, rheumatoid arthritis, and ulcerative colitis/crohn’s colitis; and EDP1503 for the treatment of colorectal cancer, renal cell carcinoma, and melanoma, as well as patients who have relapsed on prior PD-1/L1 inhibitor treatment across multiple tumor types. The company was founded in 2014 and is based in Cambridge, Massachusetts.
Latest EVLO News From Around the Web
Below are the latest news stories about EVELO BIOSCIENCES INC that investors may wish to consider to help them evaluate EVLO as an investment opportunity.
Flagship-backed microbiome biotech Evelo to shut downThe company said it had not found “a viable alternative” to closing down in the months since it hit a clinical setback and laid off staff. |
Horizon Technology Finance Corporation (NASDAQ:HRZN) Q3 2023 Earnings Call TranscriptHorizon Technology Finance Corporation (NASDAQ:HRZN) Q3 2023 Earnings Call Transcript November 1, 2023 Operator: Greetings, and welcome to Horizon Technology Finance Corporation Third Quarter 2023 Earnings Call. At this time, all participants are in a listen-only mode. A brief question-and-answer session will follow the formal presentation. [Operator Instructions] As a reminder, this conference is being […] |
Q3 2023 Horizon Technology Finance Corp Earnings CallQ3 2023 Horizon Technology Finance Corp Earnings Call |
Evelo (EVLO) Drops 59% on Flunking Psoriasis Drug StudyEvelo's (EVLO) EDP2939 fails to achieve the primary endpoint in a mid-stage for treating moderate psoriasis. The company decides to cease clinical development on the candidate. |
Biotech Stock Roundup: ALDX, EVLO Down on Setback, SRRK Offers Updates & MoreRegulatory and pipeline updates from Aldeyra Therapeutics (ALDX) and Scholar Rock (SRRK) are in focus in the biotech sector. |
EVLO Price Returns
| 1-mo | -10.71% |
| 3-mo | -9.26% |
| 6-mo | -93.75% |
| 1-year | -98.44% |
| 3-year | -99.98% |
| 5-year | -99.97% |
| YTD | -18.70% |
| 2023 | -99.81% |
| 2022 | -73.48% |
| 2021 | -49.79% |
| 2020 | 197.78% |
| 2019 | -68.79% |
Loading social stream, please wait...